Gamida Cell
Jerusalem
About Gamida Cell
Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases. Its product includes NiCord, a cell therapy based on NAM-expanded cord blood developed to improve and extend the life-saving benefits of hematopoietic stem cell transplant. The company applies an expansion platform supporting the properties of NAM to allogeneic cell sources that include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $292.8M
- Funding stage: IPO
- Last round: Post-IPO Debt (Sep 2022)
- Ticker: nasdaq:GMDA
- Website: gamida-cell.com
- Phone: 97226595616
Industries & Categories
Biotechnology, Health Care, Life Science, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/gamida-cell-50380 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.